A New Era of Cancer Treatment

We have one of the leading pipelines in cell therapy within the industry

Our pipeline includes investigational therapies and next generation technologies for a range of hematologic malignancies and solid tumors.

Chimeric Antigen Receptor (CAR)

Trial Area of Research Pre-Ind Phase 1 Phase 2/3

axicabtagene ciloleucel

ZUMA-1

DLBCL, PMBCL & TFL

ZUMA-5

Indolent NHL

ZUMA-6

DLBCL (PD-L1 mAb)

ZUMA-7

DLBCL (2nd line)

ZUMA-9 (Expanded Access)

Aggressive NHL

KTE-C19

ZUMA-2

MCL

ZUMA-3

Adult ALL

ZUMA-4

Pediatric ALL

ZUMA-8

CLL

Human anti-CD19 (2nd Gen)

NCI

Heme Malignancies

Humanized anti-CD19 Control CAR (3rd Gen)

Heme Malignancies

KITE-585 (anti-BCMA)

MM

KITE-796 (anti-CLL-1 Control CAR)

AML

T Cell Receptor (TCR)

Trial Area of Research Pre-Ind Phase 1 Phase 2/3

MAGE A3/A6

NCI

Solid Tumor

KITE-718 (MAGE A3/A6)

Solid Tumor

MAGE A3

NCI

Solid Tumor

HPV-16 E6 & E7

NCI

Cervical and HNC

KITE-439 (HPV-16 E7)

Cervical and HNC

KRAS

NCI

Solid Tumor

SSX-2

NCI

Solid Tumor

Neoantigens

NCI

Solid Tumor

DLBCL = diffuse large b-cell lymphoma

PMBCL = primary mediastinal b-cell lymphoma

TFL = transformed follicular lymphoma

NHL = non-Hodgkin lymphoma

CLL = chronic lymphocytic leukemia

MM = multiple myeloma

MCL = mantle cell lymphoma

AML = acute myeloid leukemia

ALL = acute lymphoblastic leukemia

Kite Pharma Expanded Access Policy

Treating physicians may request information about Expanded Access for a Kite Pharma therapy by contacting Kite Medical Information at 1-844-454-KITE.

Kite will evaluate these requests individually. Kite may provide physician requested Expanded Access for a Kite therapy for patients with no other available therapies and for patients who are not eligible to participate in a current Kite clinical trial. Kite will acknowledge receipt of the request via telephone call or email within 5 business days of receipt of the request.

Information on all Kite trials can be found on ClinicalTrials.gov.

Pursuant to the 21st Century Cures Act: the posting of policies by manufacturers and distributors shall not serve as a guarantee of access to any specific investigational therapy by any individual patient.